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BACKGROUND: In a genome-wide scan (GWS) of 175 multiplex prostate cancer (PCa) families from the University of Michigan
Prostate Cancer Genetics Project (PCGP), linkage was observed to markers on chromosome 17q21–24, a region that includes
two breast cancer susceptibility genes, BRCA1 and BRIP1. BRIP1 is a Fanconi anaemia gene (FANCJ) that interacts with the BRCT
domain of BRCA1 and has a role in DNA damage repair. Protein truncating mutations in BRIP1 have been identified in hereditary
breast and ovarian cancer families, and a recent report suggested that a recurrent truncating mutation (R798X) may have a role
in PCa susceptibility.
METHODS: We examined the role of BRIP1 mutations in hereditary PCa through sequence analysis of 94 individuals from PCGP
families showing linkage to 17q.
RESULTS: A total of 24 single-nucleotide polymorphisms, including 7 missense variants but no protein truncating mutations,
were observed.
CONCLUSIONS: The data presented here suggest that BRIP1 truncating mutations are uncommon in PCa cases and do not account
for the linkage to chromosome 17q observed in our GWS. Additional investigation is needed to determine the significance, if any,
of the observed BRIP1 missense variants in hereditary PCa.
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Prostate cancer (PCa) is the most commonly diagnosed cancer and
the second leading cause of cancer death among American men
(Jemal et al, 2009). In addition to age and ancestry, family history
is a leading risk factor for developing PCa, suggesting that
germline genetic variation has a role in PCa development.
However, the number and identities of the genes involved in
hereditary PCa are still largely unknown.
There is some evidence to suggest that inherited mutations in
breast cancer (BrCa) and ovarian cancer (OvCa) risk genes BRCA1
and BRCA2 also increase the risk of PCa. Several studies have
shown that carriers of deleterious, germline mutations in BRCA2
are at an increased risk of developing PCa, especially early-onset
PCa (Risch et al, 2001; Thompson and Easton, 2002; Edwards et al,
2003; Kirchhoff et al, 2004; Agalliu et al, 2007). In addition, we
recently found that two common BRCA1 single-nucleotide
polymorphisms (SNPs) are associated with familial and early-
onset PCa (Douglas et al, 2007).
BRIP1, located at 17q22, is a Fanconi anaemia gene (FANCJ)
(Litman et al, 2005) that directly interacts with the BRCT domain
of BRCA1 (Yu et al, 2003) and has a role in DNA damage repair
(Bridge et al, 2005; Litman et al, 2005). BRIP1-deficient cell lines
are overly sensitive to DNA crosslinkers cisplatin and mitomycin C
(Bridge et al, 2005; Litman et al, 2005), arrest in the S-phase
of the cell cycle, and exhibit increased chromosomal instability
(Kumaraswamy and Shiekhattar, 2007). Recently, BRIP1 has been
identified as a BrCa susceptibility gene. Seal et al (2006) found that
carriers of truncating BRIP1 mutations have a relative risk of BrCa
of 2.0. The functional relationship between BRIP1 and BRCA1 and
their roles in hereditary BrCa make BRIP1 a biologically plausible
candidate PCa susceptibility gene.
Prostate cancer linkage studies have identified several areas of
the genome that may harbour susceptibility loci, although signals
have often been difficult to reproduce between research teams
(Schaid, 2004). The University of Michigan Prostate Cancer
Genetics Project (PCGP) was the first group to report PCa linkage
to chromosome 17q markers (Lange et al, 2003). Chromosome 17q
linkage has subsequently turned out to be one of the strongest
(Lange et al, 2007) and most reproducible (Gillanders et al, 2004;
Xu et al, 2005) linkage signals for hereditary PCa. BRIP1 is B20cM
downstream from BRCA1 and both are contained near or within
our linkage signal. Previous research from our laboratory failed to
identify deleterious BRCA1 truncating mutations in chromosome
17-linked families (Zuhlke et al, 2004). In this study, we examine
the role of germline BRIP1 variation in hereditary PCa, focusing on
families with linkage evidence to 17q markers.
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Patient selection
A genome-wide linkage scan was previously performed on 175
families from the PCGP. To be eligible for the scan, families had to
meet one of the following criteria: (1) three or more individuals
diagnosed with PCa at any age in X3 generations or (2) two or
more individuals diagnosed with PCa before the age of 55 years.
The most significant evidence for linkage was observed at B60cM
on chromosome 17, with 95 families showing some evidence of
linkage (non-parametric linkage score 40 at 60.1cM on chromo-
some 17, which is the linkage peak from our first genome-wide
scan (GWS) (Lange et al, 2003)). One individual was selected from
each of 94 linked families and was included in this analysis,
including 88 men with PCa and 6 women with BrCa. The selected
men were either the youngest PCa case in the family (with DNA
available) or an older case in a first- or second-degree relationship
with a woman with BrCa. The women selected were all first-degree
relatives of at least one man with PCa. The number of BrCa
and OvCa cases in each family, as reported in family history
surveys, was calculated. PCa cases were confirmed by medical
record when possible.
Sequencing
All BRIP1 exons and intron–exon boundaries were amplified by
PCR and directly sequenced in each individual. PCR conditions
and primer sequences are available on request. Sequencing reactions
were performed using Big Dye Terminator v1.1 chemistries (Applied
Biosystems, Foster City, CA, USA). Products were then analysed
using an ABI 3100 Genetic Analyzer (Applied Biosystems). Sequences
were screened for variants using Mutation Surveyor v2.61 software
(SoftGenetics, State College, PA, USA).
RESULTS
Table 1 shows the clinical characteristics of the 94 PCGP families
with linkage to chromosome 17 markers. Of the families, 83 were
Caucasian, 10 were African American, and 1 was Asian American.
There were an average of 4.1 confirmed PCa cases per family, and
the average age of diagnosis of confirmed PCa cases across families
was 63.4 years. In all, 37 families had at least 1 BrCa case and
8 families had at least 1 OvCa case. Five families had both BrCa
and OvCa cases. We used the software, Merlin (http://www.sph.
umich.edu/csg/abecasis/Merlin/index.html), to calculate the Kong
and Cox maximum LOD score on the basis of the expo-
nential model and ‘pairs’ non-parametric allele-sharing statistic
at the BRIP1 locus for the families of the 94 patients included in
the sequence analysis (Whittemore and Halpern, 1994; Kong and
Cox, 1997; Abecasis et al, 2002). The LOD score was 8.26 in these
families at the BRIP1 locus.
The 94 individuals sequenced here included 88 men with
PCa and 6 women with BrCa. The PCa cases had a median age
of diagnosis of 55.5 years, and BrCa cases had a median age of
diagnosis of 61.5 years (Table 2). The median pre-diagnosis PSA
of PCa cases was 6.15ngml
 1. The majority of men with PCa were
treated surgically, and B78% had localised disease at diagnosis.
Overall, no truncating mutations were observed, but a total of
24 SNPs were identified in the sequenced regions of the BRIP1 gene
(Table 3). In total, 11 of these SNPs were located in coding regions,
including 7 non-synonymous SNPs, 5 SNPs in BRIP1 untranslated
regions, and 8 intronic SNPs. Six of the seven non-synonymous
SNPs were observed in only one to two individuals. However, the
minor allele of S919P was present in 55 of the 94 individuals and
had an allele frequency of B37%. Overall, none of the individuals
was invariant at all 24 SNPs. A total of 59 individuals had at least
one missense variant. One individual was heterozygous for three
missense variants.
Further analyses were conducted to evaluate the potential
function of observed variants. All missense variants were analysed
using SIFT (http://sift.jcvi.org/) and PolyPhen (http://genetics.
bwh.harvard.edu/pph/) (Ramensky et al, 2002; Ng and Henikoff,
2006), which are computer programmes that use structural and
phylogenetic data to predict the functional impact of amino-acid
changes. Two SNPs, R264W and R419W, were predicted to be
deleterious by both programmes. These SNPs, which were each
observed in only one individual, were typed in additional family
members. In one family, R264W accounted for two out of three
PCa cases and was not present in the unaffected brother of the
proband, who was the only unaffected male with DNA available for
Table 1 Characteristics of chromosome 17-linked families (n¼94)
N (%) or mean (range)
Ancestry
Caucasian 83 (88)
African American 10 (11)
Asian American 1 (1)
Number of PCa cases per family
Confirmed 4.1
Total 4.3
Mean age at diagnosis of confirmed PCa cases 63.7 (45.7–78.3)
Number of families with BrCa cases
0 57 (61)
1–2 31 (33)
42 6 (6)
Number of families with OvCa cases
0 86 (92)
1–2 8 (9)
42 0 (0)
Abbreviations: BrCa¼breast cancer; OvCa¼ovarian cancer; PCa¼prostate cancer.
Table 2 Characteristics of sequenced individuals
N (%) or median (interquartile range)
Sex
Male – PCa cases 88 (94)
Female – BrCa cases 6 (6)
BrCa cases
Age at diagnosis 61.5 (50.25–63.75)
PCa cases
Age at diagnosis 55.5 (50–60)
Pre-diagnosis PSA (ngml
 1) 6.15 (3.83–9.38)
Surgery (% yes) 69 (78.4)
Gleason scores
a
o7 39 (47)
7 39( 47)
47 5 (6)
Stage
a,b
Localised 63 (78)
Locally advanced 14 (17)
Metastatic 4 (5)
Abbreviations: BrCa¼breast cancer; PCa¼prostate cancer; PSA¼prostate-specific
antigen.
aColumns do not add up to 88 due to missing data.
bLocalised¼T1 or T2,
N0 and M0 or Pre-Dx PSA o20ngml
 1; locally advanced¼T3 or T4, N0 and
M0 or Pre-Dx PSA 420ngml
 1 but o100ngml
 1; metastatic¼N1 or M1 or
Pre-Dx PSA 4100ngml
 1.
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proband and his affected brother; DNA was not available for any
other members of this family.
DISCUSSION
The location of BRIP1 near or within the strongest linkage signal
identified in a GWS of hereditary PCa families, along with its
functional interaction with BRCA1 and its role in BrCa suscept-
ibility, led us to investigate the possibility that BRIP1 is also a PCa
susceptibility gene. We screened individuals from families that
were highly enriched for both hereditary PCa and chromosome 17
linkage. No obviously deleterious, truncating mutations were
detected in the 94 unrelated individuals sequenced from chromo-
some 17-linked families. However, multiple SNPs, including 7
missense variants, were identified. Although the precise function
of these SNPs is unknown, both R264W and R419W were predicted
to be deleterious by SIFT and PolyPhen (Ramensky et al, 2002;
Ng and Henikoff, 2006).
Truncating BRIP1 mutations have been clearly implicated as
cancer susceptibility alleles. Seal et al (2006) identified five
different truncating BRIP1 mutations in nine BrCa cases from
hereditary BrCa families who had tested negative for BRCA1 and
BRCA2 mutations, and reported a relative risk of BrCa of 2.0 for
mutation carriers. Additional studies by De Nicolo et al showed
that a recombinant protein containing the novel BRIP1 truncating
mutation (2992–2995delAAGA) had decreased protein stability
and diminished ability to interact with BRCA1. Further experi-
ments using BrCa tissue from a patient carrying the same exon 20
four base-pair deletion confirmed that there was loss of the wild-
type allele in tumour cells, consistent with the model of a classical
tumour-suppressor gene (De Nicolo et al, 2008). It has also been
shown that bi-allelic, truncating mutations in BRIP1 cause Fanconi
anaemia complementation group J (Litman et al, 2005).
To date, no study has definitively shown that BRIP1 variants,
other than truncating mutations, have a role in susceptibility to
any disease. Sigurdson et al (2004) found that women who were
homozygous for the serine allele at S919P had a relative risk
of developing BrCa of B7 before the age of 50 years compared
with homozygotes for the proline allele. However, this result
was not statistically significant after adjustment for multiple
testing. Several subsequent studies have also found no association
between S919P genotype and BrCa risk (Garcia-Closas et al, 2006;
Vahteristo et al, 2006; Frank et al, 2007). Recently, two BRIP1
tagged SNPs were found to be associated with OvCa risk in case–
control samples from the United Kingdom, Denmark, and the
United States, but this association was weak and has not been
validated (Song et al, 2007).
There is only one report to date that specifically examines the
potential contribution of BRIP1 variants to PCa. Kote-Jarai et al
(2009) sequenced DNA from the youngest PCa case from each of
192 British multiplex PCa families. They identified a truncating
mutation (R798X) in only 1 of the 192 families, and this muta-
tion failed to completely segregate with PCa cases in this family.
Sequence analysis identified an additional five non-synonymous
variants, including only one variant described in our report (S919P)
that was detected in 43% of cases and 46% of controls (N¼2081).
These authors concluded that truncating BRIP1 mutations may
rarely contribute to PCa susceptibility. Although we only sequenced
cases from 94 families, compared with 192 in the report by
Kote-Jarai, our strategy of selecting chromosome 17-linked families
should have increased the likelihood of detecting BRIP1 mutations if
they segregated with PCa within these families. The fact that we did
Table 3 Germline BRIP1 mutations identified in hereditary PCa families
dbSNP ID no. Location Minor allele frequency Number of individuals Ancestry
Missense mutations
R106C Exon 3 0.005 1 Caucasian
V193I rs4988346 Exon 6 0.011 2 Caucasian, African American
L195P rs4988347 Exon 6 0.005 1 Caucasian
R264W rs28997569 Exon 7 0.005 1 Caucasian
R419W Exon 9 0.005 1 Caucasian
T686A Exon 14 0.005 1 Caucasian
S919P rs4986764 Exon 19 0.373 55 Caucasian, African American, Asian American
Synonymous mutations
L692L Exon 14 0.005 1 Caucasian
R762R Exon 16 0.005 1 African American
E879E rs4986765 Exon 19 0.282 41 Caucasian, African American, Asian American
Y1137Y rs4986763 Exon 20 0.378 56 Caucasian, African American, Asian American
UTR mutations
15 C4T5 0-UTR 0.005 1 Caucasian
4019 A4G3 0-UTR 0.011 2 Caucasian
4050 C4T rs1978111 30-UTR 0.388 56 Caucasian, African American, Asian American
4063 G4C3 0-UTR 0.005 1 African American
4375 T4C rs7213430 30-UTR 0.367 55 Caucasian, African American, Asian American
Intronic mutations
IVS1+12 C4T rs4988340 Intron 1 0.271 1 Caucasian
IVS1-3 T4C Intron 1 0.005 1 Caucasian
IVS2+15 G4A Intron 2 0.005 1 African American
IVS2-18 A4C rs2138005 Intron 2 0.005 1 African American
IVS4+78 A4G Intron 4 0.005 1 African American
IVS14+7 C4T Intron 14 0.005 1 Caucasian
IVS17+80 A4G Intron 17 0.032 5 African American
IVS19+43 A4T rs4988357 Intron 19 0.335 58 Caucasian, African American
Abbreviations: PCa¼prostate cancer; SNP¼single-nucleotide polymorphism; UTR¼untranslated region.
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mutations are unlikely to contribute to hereditary PCa.
In conclusion, our data suggest that BRIP1 truncating mutations
are not common PCa susceptibility alleles and do not account for
the chromosome 17 linkage observed in our GWS. The potential
role of the coding and non-coding BRIP1 SNPs identified in this
report remains unclear, as it is possible that a more common
genetic variation contributes to PCa risk. For example, Kote-Jarai
et al found significant PCa associations with two SNPs in intron 6
of BRIP1, which are correlated with at least one of the common
SNPs identified here (rs4988340; based on the HapMap CEU sample,
the pairwise r
2¼0.89 and 0.78 with rs6505074 and rs8076727, respec-
tively). It is possible that the chromosome 17 linkage observed in
multiplex PCGP families is because of mutations in a nearby gene,
and the more common BRIP1 variations observed by us and others
may have more subtle influences on disease susceptibility. Therefore,
follow-up association studies should be considered to assess the
possible contribution of these variants to PCa risk.
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